NASDAQ:ARAV

Aravive Stock Forecast, Price & News

$5.95

+0.15 (+2.59 %)

(As of 01/25/2021 12:00 AM ET)

Add

Compare

Today's Range

$5.71

Now: $5.95▼

$6.01

50-Day Range

$5.34

MA: $5.92▼

$6.51

52-Week Range

$3.34

Now: $5.95▼

$14.94

Volume101,636 shs

Average Volume103,216 shs

Market Capitalization$95.72 million

P/E RatioN/A

Dividend YieldN/A

Beta3.2

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.

Overall MarketRank^™

1.64 out of 5 stars

Medical Sector

270th out of 1,922 stocks

Pharmaceutical Preparations Industry

137th out of 771 stocks

3.4 Analyst's Opinion

Consensus Rating
Aravive has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.00, Aravive has a forecasted upside of 320.2% from its current price of $5.95.
Amount of Analyst Coverage
Aravive has only been the subject of 1 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Aravive has received 90 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Aravive has received 88 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Aravive has received 50.56% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Aravive and other stocks. Vote “Outperform” if you believe ARAV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARAV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Aravive does not currently pay a dividend.
Dividend Growth
Aravive does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aravive insiders have bought more of their company's stock than they have sold. Specifically, they have bought $46,080.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 30.50% of the stock of Aravive is held by insiders.
Percentage Held by Institutions
40.54% of the stock of Aravive is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Aravive are expected to grow in the coming year, from ($1.97) to ($1.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aravive is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aravive is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aravive has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ARAV

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.aravive.com

Phone936-355-1910

Employees16

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio11.37

Quick Ratio11.37

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.75 million

Price / Sales20.15

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.71 per share

Price / Book1.26

Profitability

EPS (Most Recent Fiscal Year)($1.57)

Net Income$-18,220,000.00

Net MarginsN/A

Return on Equity-47.21%

Return on Assets-39.11%

Miscellaneous

Outstanding Shares16,087,000

Market Cap$95.72 million

Next Earnings Date3/26/2021 (Estimated)

OptionableOptionable

$5.95

+0.15 (+2.59 %)

(As of 01/25/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ARAV News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter.

Aravive (NASDAQ:ARAV) Frequently Asked Questions

How has Aravive's stock price been impacted by Coronavirus (COVID-19)?

Aravive's stock was trading at $4.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARAV shares have increased by 19.2% and is now trading at $5.95.
View which stocks have been most impacted by COVID-19.

Is Aravive a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aravive stock.
View analyst ratings for Aravive or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Aravive?

Wall Street analysts have given Aravive a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aravive wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aravive's next earnings date?

Aravive is scheduled to release its next quarterly earnings announcement on Friday, March 26th 2021.
View our earnings forecast for Aravive.

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) announced its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.24.
View Aravive's earnings history.

What price target have analysts set for ARAV?

5 Wall Street analysts have issued 12 month price targets for Aravive's shares. Their forecasts range from $20.00 to $30.00. On average, they expect Aravive's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 320.2% from the stock's current price.
View analysts' price targets for Aravive or view Wall Street analyst' top-rated stocks.

Who are some of Aravive's key competitors?

Some companies that are related to Aravive include OrganiGram (OGI), TFF Pharmaceuticals (TFFP), NextCure (NXTC), Immunic (IMUX), Trevena (TRVN), Fulcrum Therapeutics (FULC), Aeglea BioTherapeutics (AGLE), Verastem (VSTM), Tricida (TCDA), VistaGen Therapeutics (VTGN), MEI Pharma (MEIP), Axovant Sciences (AXON), Concert Pharmaceuticals (CNCE), Arbutus Biopharma (ABUS) and Fortress Biotech (FBIO).
View all of ARAV's competitors.

What other stocks do shareholders of Aravive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX).

Who are Aravive's key executives?

Aravive's management team includes the following people:

Dr. Gail F. McIntyre, CEO & Director (Age 57, Pay $453.34k)
Mr. Vinay Shah, Chief Financial Officer (Age 58, Pay $463.51k)
Dr. Jeffrey L. Cleland, Co-Founder (Age 55)
Dr. Joshua Silverman Ph.D., Co-Founder
Dr. Randy L. Anderson, Sr. VP of Data Sciences
Dr. Reshma Rangwala M.D., Ph.D., Chief Medical Officer
Kenneth L. Guernsey, Sec.

What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

How do I buy shares of Aravive?

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $5.95.

How big of a company is Aravive?

Aravive has a market capitalization of $95.72 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Aravive employs 16 workers across the globe.

What is Aravive's official website?

The official website for Aravive is www.aravive.com.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]ir.com.

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here